34 results about "Remyelination" patented technology

The present disclosure provides, in one aspect, compounds, compositions, and methods for reducing and / or inhibiting the activity of p38gamma. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for promoting remyelination. In certain embodiments, the compounds, compositions, and methods of the disclosure are useful for treating, preventing, and / or ameliorating one or more diseases or disorders in a subject, including but not limited to multiple sclerosis (MS), inflammatory disease, and cancer.

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

The subject matter described herein relates to compounds of Formula A and pharmaceutically acceptable salts thereof that promote myelination, methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds to treat conditions, such as myelination-related conditions.

The present application relates to a kind of myelin repair auxiliary method based on neural signal modeling.The method obtains the multi-modal neural signal data such as electroencephalogram signal of individual to be rehabilitated and is preprocessed, forms preprocessed data set;Subsequently, individualized time series modeling process is executed, and the time series characteristic representation including nerve conduction velocity recovery rate, phase consistency and neural pathway integrity is generated, and individualized calibration is carried out by dynamic baseline updating mechanism.The calibrated feature representation is input to the pre-trained deep learning inference engine.The inference engine outputs myelin repair index and imbalance risk score, which is used to represent the degree of repair and predict future abnormal risk.Based on the above index, a set of intervention parameters is generated, including electrical stimulation intervention parameters, virtual rehabilitation training task difficulty and rehabilitation training rhythm, and further forming control instructions to configure virtual rehabilitation training environment and electrical stimulation execution interface, so as to realize the individualized assistance and dynamic optimization of myelin regeneration repair.

The disclosure provides methods for (i) treating multiple sclerosis in patient, (ii) treating a patient having symptoms of multiple sclerosis, (iii) preventing the onset of multiple sclerosis symptoms in patient having multiple sclerosis or predisposed to multiple sclerosis; (iv) promoting or enhancing immunomodulation and remyelination and / or myelin repair in a subject in need thereof; (v) a neuroinflammatory disorder; (vi) Amyotrophic Lateral Sclerosis; or (vii) a demyelinating disease or disorder or a hypomyelinating condition, each method comprising administering a therapeutically effective amount of a bryostatin compound to the patient.

The invention relates to the technical field of new application of medicines, in particular to application of G15 to treatment of white matter injury based on promotion of cerebrovascular generation, and finds that the G15 has the effect of promoting cerebrovascular generation, can promote myelination insufficiency caused by hypoxia in the early development stage and can improve neurological dysfunction caused by hypoxia, and the G15 has the effect of promoting cerebrovascular generation. Moreover, myelin sheath regeneration of a local demyelination area after the adult can be promoted, so that the effect of directly treating the white matter injury from the pathological aspect is achieved. The invention provides a new application of G15 in treating white matter injury and long-term neurological dysfunction by promoting cerebrovascular generation.

The present application provides O-GlcNAc glycosidase (O-GlcNAcase, OGA) inhibitors and their applications for promoting remyelination. Specifically, by comparing the promoting effects of different types of OGA inhibitors on OPC differentiation and remyelination in the models of OPC differentiation and remyelination, the OGA inhibitors with drugability of the present application are obtained. The OGA inhibitors of the present application have wide application value in preventing and / or treating demyelination and its related diseases.

The present invention relates to combination therapies targeting inhibitors of O-GlcNAc glycoside hydrolases and antibodies. Specifically, the invention provides application of a preparation combination of an OGA inhibitor and an antibody, and the preparation combination is used for combined treatment of demyelination and related diseases. The OGA inhibitor and the antibody are jointly applied to individuals suffering from myelin sheath injury or aplastic disorder, the promoting effect on myelin sheath regeneration and the regulating effect on immune cells can be achieved, the OGA inhibitor and the antibody have a synergistic effect, myelin sheath regeneration can be more remarkably promoted, and the OGA inhibitor and the antibody have wide application prospects in prevention and / or treatment of demyelination and related diseases.

To provide a pharmaceutical composition for treating nervous system disorders by inducing remyelination, neuroprotection, and immunomodulation.SOLUTION: A pharmaceutical composition comprising a therapeutically effective amount of a RXR agonist for use in combination with a thyroid hormone in the treatment of demyelination or neuroinflammation associated with a central nervous system disorder, the RXR agonist is 3, 7-dimethyl-6 (S), 7 (S) - methano, 7 - [1,1,4,4 - tetramethyl - 1,2,3,4 - tetrahydronaphth-7-yl] 2 (E), 4 (E) heptadienoic acid, and the RXR agonist is used in combination with a thyroid hormone to provide greater improvement in a central nervous system disorder than either the RXR agonist or the thyroid hormone alone.SELECTED DRAWING: Figure 1

The invention discloses application of steroid saponin of trillium tschonoskii maxim to preparation of a medicine for treating vascular dementia, and relates to the technical field of medicines. Animal experiments prove that the berberis apiacea steroid saponin can improve the spatial reference learning function of cerebral ischemia rats, improve the spatial reference memory function of the cerebral ischemia rats and enhance the long-term memory function of the cerebral ischemia rats. In addition, brain tissue damage and white matter structure damage of rats suffering from cerebral ischemia can be relieved, axonal myelin sheath microstructure reconstruction and white matter fiber reconstruction of the rats suffering from cerebral ischemia are promoted, and myelin sheath regeneration of rats suffering from vascular dementia is promoted. Network pharmacological analysis finds that the age grass total steroid saponin has a wide regulation effect on OPCs and OLs cell components and molecular functions, and further, OPCs differentiation myelin sheath inhibition related factors are regulated and controlled, and white matter myelin sheath regeneration is promoted.

The application belongs to the technical field of biological drugs, and particularly relates to a preparation method of genetically modified human bone marrow mesenchymal stem cells and application thereof in treating nervous system diseases, in particular, multiple sclerosis. The human bone marrow mesenchymal stem cells are double-modified by brain-derived neurotrophic factor (BDNF) and anti-S1PR5 nanobody, so that the activity of the human bone marrow mesenchymal stem cells is improved, the survival of neurons or oligodendrocytes is promoted, cell apoptosis is inhibited, and myelin regeneration is promoted, and the human bone marrow mesenchymal stem cells can be applied to nervous system diseases, in particular, multiple sclerosis.

The invention provides a composite active dressing for neural restoration and a preparation method and application thereof, and relates to the technical field of medical materials. The composite active dressing comprises a transdermal inner layer and a small extracellular vesicle slow-release outer layer, the transdermal inner layer is of a membrane-shaped structure and comprises a composite active component and a hydrogel matrix material, and the composite active component is selected from one or more of an anti-inflammatory component, a microcirculation improving component, an antioxidant component and a neurotrophic component; the small extracellular vesicle sustained-release outer layer is of a three-dimensional network structure and comprises small extracellular vesicles and a hydrogel matrix material. According to the invention, stable loading and layered deep delivery and release of the small extracellular vesicles are realized, the inflammatory response and microcirculation state of an injured part are improved, proliferation migration and remyelination of Schwann cells can be promoted, and axon regeneration and effective repair of nerve injury can also be promoted.

The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.

The invention relates to a myelin sheath repair auxiliary method based on neural signal modeling. According to the method, multi-modal neural signal data such as electroencephalogram signals of a to-be-recovered individual are obtained and preprocessed, and a preprocessed data set is formed; then, an individualized time sequence modeling process is executed, time sequence feature representation containing indexes such as the nerve conduction speed recovery rate, the phase consistency and the neural pathway integrity is generated, and individualized calibration is carried out through a dynamic baseline updating mechanism. The calibrated feature representation is input to a pre-trained deep learning inference engine. The inference engine outputs a myelin sheath repair index and an imbalance risk score for representing a repair degree and predicting a future abnormal risk. An intervention parameter set is generated based on the indexes, the intervention parameter set comprises electrical stimulation intervention parameters, virtual rehabilitation training task difficulty and rehabilitation training rhythms, and a control instruction is further formed to configure a virtual rehabilitation training environment and an electrical stimulation execution interface, so that personalized assistance and dynamic optimization of myelin sheath regeneration and repair are realized.

There is described a method for inducing lesion (preferably brain lesion) reduction in a patient in need thereof and / or Apparent Diffusion Coefficient (ADC) values (suggesting remyelination and reduced inflammation). The method comprises administering to the patient a therapeutically effective amount of ibogaine, ibogaine derivative, or a pharmaceutically acceptable salt and / or solvate thereof.

The invention provides walnut-derived extracellular membrane vesicles and application thereof in peripheral nerve injury repair, and relates to the technical field of biological medicines. The walnut-derived extracellular membrane vesicles (WEVs) prepared by the invention show typical vesicle form and nano-scale particle size distribution, and can still keep structural integrity after freeze-drying and long-term storage, thereby supporting the feasibility of standardized preparation and preservation of the walnut-derived extracellular membrane vesicles (WEVs). In the functional level, the WEVs can be efficiently internalized by Schwann cells (SCs) through an energy-dependent process, and the process accords with gridding protein mediated endocytosis characteristics; meanwhile, the WEVs show good biocompatibility and biological safety in vitro and in vivo. In addition, the WEVs can promote remyelination of PNI model rats, improve motion and sensory functions of the PNI model rats and relieve muscular atrophy conditions of the PNI model rats, and has an obvious treatment effect on the PNI model rats. The WEVs are expected to be used as a plant-derived nano candidate drug for treating peripheral nerve injury.

The invention provides application of glycopyrronium bromide in preparation of a medicine for treating nervous system diseases, and belongs to the technical field of biological medicines. The research finds that the novel drug glycopyrronium bromide shows a clear and excellent technical effect in the aspect of treating nervous system diseases, on one hand, the glycopyrronium bromide can inhibit the inflammatory response of glial cells by reducing infiltration of central mononuclear macrophages (MDM); on the other hand, differentiation and maturation of oligodendroglia precursor cells (OPCs) into oligodendroglia cells can be effectively promoted, and the effect of promoting myelin sheath regeneration is achieved. Multiple sclerosis is effectively improved through the dual effects of inhibiting glial cell inflammation and promoting myelin regeneration, and the medicine is a candidate medicine with great potential for treating progressive multiple sclerosis (MS).

The invention provides the application of SCD1 in preparing the medicine for treating the nerve myelin sheath injury diseases, the application reveals that SCD1 serves as a brand-new target spot for treating the sciatic nerve myelin sheath injury diseases for the first time, the target spot blank of existing targeted lipid metabolism regulation myelin sheath regeneration medicine is filled, and all-around repairing can be achieved from the molecule, form and function level; on one hand, the SCD1 can up-regulate expression of genes such as PMP22 and MPZ and promote myelin sheath synthesis from the source, and on the other hand, the SCD1 can also increase the myelin sheath thickness, reduce the number of non-marrow nerves and improve the structural integrity and stability of regenerated myelin sheaths; meanwhile, the SCD1 can prolong the dwell time of the rotating rod, accelerate the nerve conduction speed and improve dyskinesia and nerve conduction abnormity after sciatic nerve injury; besides, regulation of endogenous lipid metabolism is taken as a core mechanism, an intervention mode is safe and controllable, an experimental system is mature and repeatable, and an efficient, stable and safe new strategy is provided for clinical treatment of sciatic nerve myelin sheath injury.

The present disclosure is directed to methods of increasing remyelination in subjects in need thereof.

The application discloses application of dimethyl mercaptopropionic acid and relates to the field of medicine. Specifically, the application provides application of dimethyl mercaptopropionic acid in preparation of a medicine for treating Alzheimer's disease. In the application, the dimethyl mercaptopropionic acid can reverse changes in protein expression levels of MAG, CD9 and P2ry12 in the brain of an Alzheimer's disease model mouse, plays a role in myelin regeneration protection and nerve immune regulation, can reduce expression levels of pathological proteins A beta and tau related to Alzheimer's disease, improves spatial learning ability and spatial memory ability of the Alzheimer's disease mouse, and can be used for treating Alzheimer's disease.

The present disclosure relates to methods and compositions using RAP, a derivative of RAP, a variant of RAP, or a fragment of RAP to inhibit LRP1, a myelin debris receptor. The methods and compositions involve increasing, promoting, restoring, and / or enhancing differentiation of oligodendrocyte progenitor cells, myelin protein expression, mature oligodendrocyte marker expression, and / or myelination. The methods and compositions disclosed herein inhibit or block pathological activation of RhoA in OPCs. The methods and compositions also involve alleviating one or more symptoms of MS and treating MS, including slowing or stopping MS progression.

The invention relates to the field of biological medicine, and provides a pharmaceutical composition for repairing peripheral nerve injury and application of the pharmaceutical composition. The pharmaceutical composition comprises a growth arrest specific protein 6 and a caspase-1 inhibitor, and the growth arrest specific protein 6 and the caspase-1 inhibitor can be jointly administered to promote functional recovery after peripheral nerve injury. The combined strategy can inhibit adverse effects on Tyro3 (TAM receptor family member) caused by activation of inflammasome-related caspase-1, and enhance Gas6-Tyro3-related downstream survival promotion and myelination promotion signal pathways at the same time, so that the myelination regeneration and wrapping capability of Schwann cells on damaged axons can be improved, and regeneration and repair of peripheral nerves can be promoted. The pharmaceutical composition can be prepared into an injection, a solution, a gel or a sustained release preparation. The medicine kit can be packaged separately and matched with a specification to realize combined administration.

This invention provides the use of dicyclohexanone oxaloyl dihydrazone in stroke medications and a stroke medication itself. The use includes the application of dicyclohexanone oxaloyl dihydrazone in the preparation of medications for treating stroke, particularly ischemic stroke. This invention effectively promotes myelin regeneration and neurological function repair in the very early post-stroke period (e.g., within 24 hours) by targeting and regulating the "ceruloplasmin-iron metabolism-myelin regeneration" axis. The specific mechanisms include upregulating ceruloplasmin expression in the brain, enhancing its ferrooxidase activity, promoting iron transport and reuse in the brain, thereby promoting the survival, differentiation, and myelination of oligodendrocyte precursor cells. Animal experiments show that stroke model mice exhibit significant improvement in neurological function as early as day 1 after administration, with a faster onset of action than existing technologies. This invention has the advantages of rapid onset of action, clear target, and comprehensive repair effects, and has promising clinical application prospects.

New uses of populations of motor neural progenitor cells are provided, including reducing reactive astrocytes, reducing glial scars, inhibiting reactive astrocyte-mediated axonal regeneration impairment, neuronal and / or oligodendrocyte death, priming for altering protein factor expression profiles in cerebrospinal fluid, promoting axonal regeneration and / or recovery, reducing demyelination, and promoting remyelination and / or increasing myelin thickness, among others.

Relapsing remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis, affecting more than 80% of MS patients. RRMS is comprised of two phases: the auto-inflammatory episodes, in which the immune system is actively destroying myelin, alternate with remission phases. Currently there is no cure for this devastating disease. The present disclosure provides compositions and methods useful for inducing remyelination. The methods are useful for promoting remyelination to treat diseases and disorders such as MS. The present disclosure describes compositions and methods useful for inhibiting LRP1 activity. In one aspect, a siRNA against LRP1 can be used. It is disclosed that myelination can be regulated by inhibiting the interaction of LRP1 and p75NTR and that it inhibits activation of Rho-A.

Disclosed herein are compounds, compositions, and methods for inhibiting CYP51. Also disclosed herein are methods of promoting myelination and treating myelin-related disorders (e.g., multiple sclerosis).

This invention belongs to the field of biomedical technology and discloses the application of the SSRP1 gene as a target in the preparation of drugs for the prevention or treatment of NMOSD. These drugs contain components that target and interfere with the SSRP1 gene or its expression. This invention creatively discovers the application of the SSRP1 gene as a target in the preparation of drugs for the prevention or treatment of NMOSD. Knockdown of SSRP1 can alleviate motor balance impairment in NMOSD, improve the severity of demyelination damage in NMOSD, improve the myelin regeneration microenvironment in NMOSD, alleviate microglial activation caused by NMOSD, alleviate microglial-mediated neuroinflammation in NMOSD, and alleviate microglial ferroptosis in NMOSD. Therefore, it can be applied to the preparation of drugs for the treatment of NMOSD and has good clinical application value.

Described herein are methods of promoting remyelination in a subject having a demyelinating disease by administering to the subject a combination of a steroid hormone and a Hedgehog signaling pathway modulator. Also described are methods of administering a combination of pharmaceutical products, wherein the combination of pharmaceutical products is in a composition suitable for nasal administration.

The application of β-asarone ether in the preparation of drugs for promoting myelin regeneration, for improving neurological dysfunction in organisms with myelin injury, inhibiting inflammatory demyelination in the central nervous system, and enhancing memory and cognitive function.

This invention discloses the application of a PITPα regulator in the preparation of drugs for white matter remyelination repair. This invention increases the expression level of phospholipid transporter α (PITPα) in oligodendrocyte precursor cells by using a PITPα regulator, promoting oligodendrocyte maturation, differentiation, and remyelination, thereby improving white matter structure and neurological function outcomes after ischemic brain injury. The PITPα regulator used is a lipid nanoparticle encapsulating PITPα mRNA, or further, a targeting ligand for oligodendrocyte precursor cells is attached to the surface of the lipid nanoparticle. This invention provides a novel treatment strategy for ischemic brain injury.